Dihydrofolate reductase activity in adriamycin and methotrexate sensitive and resistant P388 leukemia cells.
P388 murine leukemia cells 18.4-fold more resistant to methotrexate (MTX) than the parent, drug susceptible line, were shown to possess a 1.5-fold higher dihydrofolate reductase (EC1.5.1.3) (DHFR) activity. This is in contrast to a MTX-resistant line, obtained from adriamycin-resistant cells, which is 27.9-fold more resistant to MTX and exhibits a 22.4-fold higher DHFR activity than that of the parent. The susceptibility of the enzyme to inhibition by MTX does not markedly change with the acquired drug resistance of the cell lines studied. Thus MTX-resistant cells obtained from an adriamycin-resistant line acquired resistance due to increased activity of the target enzyme, whereas other mechanisms are responsible for the resistance of cells derived from the adriamycin-sensitive parent.
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004317:Doxorubicin / Q000494:pharmacology*; D004351:Drug Resistance; D005493:Folic Acid Antagonists; D007941:Leukemia P388 / Q000201:enzymology*; D007942:Leukemia, Experimental / Q000201:enzymology*; D008727:Methotrexate / Q000494:pharmacology*; D051379:Mice; D013762:Tetrahydrofolate Dehydrogenase / Q000378:metabolism*
D005493:Folic Acid Antagonists; D004317:Doxorubicin; D013762:Tetrahydrofolate Dehydrogenase; D008727:Methotrexate